Claire Wainwright

12PUBLICATIONS
42CO-AUTHORS
Medical infection agents (incl. prions)Gene and molecular therapyInfant and child healthCancer therapy (excl. chemotherapy and radiation therapy)Disease surveillance
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 27, 2026
Multiple defects in macrophage antibacterial responses support intracellular survival of Mycobacterium abscessus in cystic fibrosis.

|Sep 08, 2025
Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies after Rapid Adoption: A Dual-Approach Study.

Pedro Miranda Afonso, Grace C Zhou, Weiji Su

|Apr 10, 2025
Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study.

Marcus A Mall, Claire E Wainwright, Julian Legg

|Feb 04, 2025
SHIFTing goals in cystic fibrosis-managing extrapulmonary disease in the era of CFTR modulator therapy; Proceedings of the International Shaping Initiatives and Future Trends (SHIFT) Symposium.

Jonathan E M O'Donnell, Lucy A Hastings, Julie N Briody

|Jul 11, 2022
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study.

Marcus A Mall, Rossa Brugha, Silvia Gartner

|Jan 19, 2020
Current infection control practices used in Australian and New Zealand cystic fibrosis centers.

Rebecca Elizabeth Stockwell, Michelle ELizabeth Wood, Emma Ballard

Pageof 2

Frequent Collaborators

2 joint publications

Marcus A Mall

2 joint publications

Tonia A Douglas

2 joint publications

Scott Cameron Bell

1 joint publications

Matthew D Wong